The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went public via a merger with a special purpose acquisition company (SPAC) in 2021 ...

Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, ...

Lemonaid's service covers conditions like urinary tract infections (UTIs), birth control, acne, hair loss, hypothyroidism, erectile dysfunction, sexually-transmitted diseases, and insomnia ...

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

Me (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider.Stay Ahead of the ...

This article isn't about Aquaphor anyway, it's about Lanolips — the Australian beauty brand that infuses hydrating lanolin into all of its products — including its Lemonaid Scrubba-Balm ...

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.